Please login to the form below
II-ON
This page shows the latest II-ON news and features for those working in and with pharma, biotech and healthcare.
Astellas to support development of Taysha’s AAV-based gene therapy programmes
issues. GAN is caused by an abnormality in a gene that encodes for the gigaxonin protein found on chromosome 16. ... Also commenting on the deal, RA Session II, Taysha’s chief executive officer, said: “We are excited to enter this strategic
Latest news
-
Sangamo’s first gene-editing trial doesn’t convince investors
II and cause the widespread tissue and organ damage that eventually shortens patients’ lives. ... Withdrawal from weekly ERT infusions would be “a very meaningful outcome” for patients with MPS II, he added.
-
NICE clears Ipsen’s Cabometyx in first-line kidney cancer
NICE’s recommendation was based on results from the phase II CABOSUN study, which showed that Cabometyx met the primary endpoint of demonstrating a statistically significant and clinically meaningful improvement in ... The approval is a reverse on
-
FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer
Maier added: “This approval builds on our heritage of bringing immuno-oncology therapies to patients with other types of thoracic cancers. ... The approval was based on data from the phase I/II trial programme CheckMate 032, which showed a median
-
Biogen and Eisai claim mid-stage win for Alzheimer’s drug
Says drug slowed down progression of cognitive decline. Biogen and Eisai say their amyloid-targeting drug BAN2401 appears to slow down cognitive decline in a phase II trial in Alzheimer’s ... Lilly’s solanezumab were unable to show much more than a
-
Daily Brief: Europe changes mind on Puma drug, Pfizer's Healthcare Hub, AbbVie and Calico add $1bn to anti-ageing quest
The latest from pharma, biotech and healthcare. Europe changes mind on Puma’s breast cancer drug. ... phase II and III studies.
More from news
Approximately 1 fully matching, plus 130 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2017
Ionis has recently received a $75m milestone payment from Bayer having successfully completed a phase II study on IONIS-FXIRx in patients with end-stage renal disease on haemodialysis. ... Amendment to 2015 agreement. 80. Inovio Pharmaceuticals/
-
Oral biologics delivery still elusive
1 agonist that recently completed a phase II study. ... Israeli company Oramed whose ORMD-0801 candidate is in phase II.
-
Pharma deals in May 2015
Making an upfront payment of $5m, the deal carriesmilestones of $105m for the phase II-ready asset. ... The option is exercisable on completion of the phase II studies in acute kidney injury related to sepsis.
-
Pharma deals in April 2015
In a phase II study on DLBC SAR3419 achieved a 43.9% objective response rate, to which investigators heralded its potential as a second-line therapy. ... milestones and 4SC will be entitled to double-digit royalties on products sales on resminostat.
-
Choices, choices: the rapidly evolving HIV treatment landscape
However, the II component of Triumeq (dolutegravir, brand name Tivicay) has experienced rapid uptake in Germany and is competing with established antiretrovirals. ... The question is, which II-containing STR will physicians prescribe? The first
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Flex Pharma appoints new R&D president
In partnership with CMO Tom Wessel, my former Sepracor colleague, we are poised to execute on our US phase II development plans.”. ... With their successful partnership from their time at Sepracor, Bill and our CMO, Dr Tom Wessel, are a great team to
-
Parexel strengthens clinical leadership
Dr Andersson's specific responsibilities include managing client relationships for phase II and phase III programmes on a global basis. ... This follows on from his role at Accenture where he oversaw technology, consulting and business services for
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
The era of digital wellbeing
But what are these tech giants doing to try and improve the negative impact of their platforms on mental health? ... Whether you need a break from your smartphone or looking to move on for good, the Light Phone II is a simple phone with only a few
-
A forward march for adaptive designs
While the observed relationship between dose and efficacy for many drugs is often non-linear, the majority of phase II trials reported on ClinicalTrials.gov in the ten years between 2002 ... Getting the dose right at phase II has become a rallying cry
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- Actinic keratosis – a common skin condition that can lead to skin cancer
- The paper trail
- Medscape Education’s Large Presence at IDWeek 2023
- WHO recommends second malaria vaccine for children
- Sanofi enters agreement with Janssen to develop E. coli vaccine candidate
- NFID and CDC urge US adults to get vaccinated against flu and COVID-19
No results were found
PMHub
Genesis Research
Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
